Fitzgerald Meghan sold (to issuer) $86K of THC

Fitzgerald Meghan sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · Fitzgerald Meghan
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides transparency on insider ownership but does not include operational, regulatory, or financial catalysts.

02

Market read

Traders may briefly reassess insider alignment, but the transaction type (sale to issuer) suggests limited fundamental signal.

03

What to watch

No 10b5-1 plan is listed, so traders may scrutinize whether the sale was discretionary; also, the issuer’s buyback mechanics could affect float and liquidity.

Relevance 6/10Timing: Same-day/next-session read-through only; insider Form 4s rarely drive sustained moves without corroborating news.

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare director Fitzgerald Meghan.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Fitzgerald Meghan sold 493 shares to the issuer for about $85.7K at $173.78/share, per SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely noise unless repeated or paired with other negative disclosures.

Evidence & confidence

The filing specifies code D (sale to issuer) and notes no 10b5-1 plan; however, the transaction type is typically mechanical and not tied to new fundamentals.

Market effects

Minimal; single insider transaction in a healthcare services name does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

If the director’s sale is part of a broader pattern of trimming, it could slightly increase perceived overhang despite the code D classification.

Key entities

  • Tenet Healthcare Corp

    Subject of the SEC Form 4 insider transaction; director sold shares to the issuer (code D).

  • Fitzgerald Meghan

    Director who sold 493 shares to the issuer at $173.7800/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.